A monoclonal antibody to treat multiple myeloma in patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulator, or who are double refractory to these agents.

If you have a Hayes login, click here to view the full report on the Knowledge Center.